A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma

Autor: Ailawadhi, Sikander, Kelly, Kevin R., Vescio, Robert A., Jagannath, Sundar, Wolf, Jeffrey, Gharibo, Mecide, Sher, Taimur, Bojanini, Leyla, Kirby, Maurice, Chanan-Khan, Asher
Zdroj: In Clinical Lymphoma, Myeloma and Leukemia January 2019 19(1):29-34
Databáze: ScienceDirect
Externí odkaz: